Market closedNon-fractional
Marinus Pharmaceuticals/MRNS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Ticker
MRNS
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Radnor, United States
Employees
166
Website
marinuspharma.com
MRNS Metrics
BasicAdvanced
$66M
Market cap
-
P/E ratio
-$2.64
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$66M
Beta
1.11
Financial strength
Current ratio
3.07
Quick ratio
2.731
Long term debt to equity
-564.16
Total debt to equity
-564.16
Interest coverage (TTM)
-7.86%
Management effectiveness
Return on assets (TTM)
-46.11%
Return on equity (TTM)
-423.43%
Valuation
Price to revenue (TTM)
2.334
Price to book
-4.01
Price to tangible book (TTM)
-4.01
Price to free cash flow (TTM)
-0.579
Growth
Revenue change (TTM)
30.53%
Earnings per share change (TTM)
220.08%
3-year revenue growth
100.23%
3-year earnings per share growth
2.55%
What the Analysts think about MRNS
Analyst Ratings
Majority rating from 11 analysts.
MRNS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.6M
7.04%
Net income
-$39M
-7.43%
Profit margin
-507.89%
-13.52%
MRNS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.61
-$0.61
-$0.74
-$0.68
-
Expected
-$0.72
-$0.66
-$0.62
-$0.66
-$0.59
Surprise
-14.89%
-7.66%
18.80%
2.80%
-
MRNS News
AllArticlesVideos
![The Schall Law Firm Initiates An Examination Into Marinus Pharmaceuticals Inc And Urges Affected Investors To Establish Contact](https://cdn.snapi.dev/images/v1/y/o/press9-2511610.jpg)
The Schall Law Firm Initiates An Examination Into Marinus Pharmaceuticals Inc And Urges Affected Investors To Establish Contact
Accesswire·4 hours ago
![Marinus Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS](https://cdn.snapi.dev/images/v1/a/r/press9-2511379.jpg)
Marinus Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
Accesswire·21 hours ago
![Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders](https://cdn.snapi.dev/images/v1/q/h/press8-2511378.jpg)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders
Accesswire·21 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Marinus Pharmaceuticals stock?
Marinus Pharmaceuticals (MRNS) has a market cap of $66M as of July 06, 2024.
What is the P/E ratio for Marinus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Marinus Pharmaceuticals (MRNS) stock is 0 as of July 06, 2024.
Does Marinus Pharmaceuticals stock pay dividends?
No, Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Marinus Pharmaceuticals dividend payment date?
Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Marinus Pharmaceuticals?
Marinus Pharmaceuticals (MRNS) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
![Buy or sell Marinus Pharmaceuticals stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Marinus Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.